Loading...
•
Sep 30, 2022
West Pharma Q3 2022 Earnings Report
Announced third-quarter 2022 results and updated full-year 2022 financial guidance.
Key Takeaways
West Pharmaceutical Services reported a decrease in net sales by 2.8% to $686.9 million, with organic net sales growth of 4.3%. Reported-diluted EPS decreased by 31.2% to $1.59, and adjusted-diluted EPS declined by 1.5% to $2.03. The company updated its full-year net sales guidance to $2.830 billion to $2.840 billion and adjusted-diluted EPS guidance to $8.15 to $8.20.
Net sales declined 2.8% to $686.9 million; organic net sales growth was 4.3%.
Reported-diluted EPS decreased 31.2% to $1.59.
Adjusted-diluted EPS decreased 1.5% to $2.03.
Full-year 2022 net sales guidance updated to $2.830 billion to $2.840 billion; adjusted-diluted EPS guidance updated to $8.15 to $8.20.
West Pharma
West Pharma
West Pharma Revenue by Segment
Revenue by Segment
Proprietary Products Revenue
CapyFin.comContract-Manufactured Products Revenue
CapyFin.com Forward Guidance
Full-year 2022 net sales are expected to be in the range of $2.830 billion to $2.840 billion. Full-year 2022 adjusted-diluted EPS is expected to be in the range of $8.15 to $8.20.
Challenges Ahead
- Net sales guidance includes an estimated fourth-quarter 2022 headwind of approximately $60 million due to foreign currency exchange rates.
- Fourth-quarter adjusted-diluted EPS guidance includes a $0.17 headwind based on current foreign currency exchange rates.
- The revised guidance includes a $0.16 EPS positive impact from the first nine-months 2022 tax benefits from stock-based compensation.
- EPS guidance range assumes a tax rate of 23% and does not include potential tax benefits from stock-based compensation for the fourth-quarter 2022.
- Full-year 2022 capital spending is expected to be in a range of $300 million to $320 million, compared to prior guidance of $380 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income